News | November 24, 2010

Trial Results Announced for Peripheral Drug-Eluting Stent

November 24, 2010 – Results for a trial comparing a drug-eluting stent to balloon angioplasty and bare metal stenting in treating restenosis after angioplasty were announced at the VEITHsymposium. The Zilver PTX drug-eluting stent met the trial's 12-month primary endpoints.

The stent has CE mark approval in Europe for the superficial femoral artery.

Michael Dake, professor of cardiothoracic surgery, Stanford University School of Medicine, said that 479 patients were enrolled at 56 institutions in the United States, Japan and Germany. Of those, 241 patients were randomized to the Zilver PTX group and 238 to the percutaneous transluminal angioplasty (PTA) group. Demographics and lesion characteristics were similar for the groups. Approximately half the PTA group experienced acute failure and underwent secondary randomization, assigning 59 and 61 patients to provisional stenting with Zilver BMS and Zilver PTX, respectively.

"The study results met the 12-month primary endpoint goals showing non-inferior EFS and superior patency for the Zilver PTX compared to PTA,” Dake said. “There was also significant clinical improvement with the Zilver PTX. Patients with de novo or artery re-narrowing, or restenosis, after angioplasty were randomized to PTA or Zilver PTX stent placement. PTA patients experiencing acute failure underwent secondary randomization to provisional stenting with Zilver BMS or Zilver PTX. Endpoints included event-free survival, stent integrity by radiographic core laboratory analysis, and primary patency by Duplex ultrasound core laboratory analysis.”

The results of this randomized, multicenter study support the safety and effectiveness of the stent.

For more information:

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Ra Medical Systems Granted Broad Patent for DABRA Catheter
News | Peripheral Artery Disease (PAD)| August 09, 2017
August 9, 2017 — Ra Medical Systems announced that the United States Patent and Trademark Office (USPTO) has granted
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Overlay Init